Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 14576 - 14600 of 15360 in total
Experimental
Illicit
Cenerimod has been used in trials studying the treatment of Systemic Lupus Erythematosus.
Investigational
CTS-21166 is a small-molecule beta-secretase inhibitor, which is being developed as a disease-modifying treatment for Alzheimer's disease. CTS-21166 is the only BACE1 inhibitor that has passed Phase I clinical trial thus far. In 2008, CoMentis revealed this small compound as a transition-state analog inhibitor (structure is currently undisclosed) with excellent...
Investigational
Matched Description: … currently undisclosed) with excellent properties in brain penetration, selectivity, metabolic stability, and
NLX-P101, gene therapy is developed by Neurologix to treat Parkinson’s disease. The gene is glutamic acid decarboxylase (GAD), whose product synthesizes the major inhibitory neurotransmitter in the brain, (gamma)-aminobutyric acid (GABA), and targets the subthalamic nucleus (STN), which is overactive in patients with Parkinson’s disease. NLX-P101 is being evaluated as...
Investigational
Matched Description: … product synthesizes the major inhibitory neurotransmitter in the brain, (gamma)-aminobutyric acid (GABA), and
Rabeximod is an orally administered compound for treatment of moderate or severe active rheumatoid arthritis that is currently undergoing phase II clinical testing in eight European countries.
Investigational
β-Hydroxythiofentanyl is an analgesic of the opioid class. This drug is an analog of fentanyl, a potent opioid.
Illicit
Experimental
Experimental
Daniquidone has been used in trials studying the treatment of Neoplasms.
Investigational
CHS-828 has been used in trials studying the treatment of Unspecified Adult Solid Tumor, Protocol Specific.
Investigational
Displaying drugs 14576 - 14600 of 15360 in total